Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Non-Current Assets (2023 - 2025)

Historic Non-Current Assets for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to $44.4 million.

  • Tonix Pharmaceuticals Holding's Non-Current Assets fell 17.32% to $44.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $175.4 million, marking a year-over-year decrease of 4181.22%. This contributed to the annual value of $43.9 million for FY2024, which is 5886.36% down from last year.
  • As of Q3 2025, Tonix Pharmaceuticals Holding's Non-Current Assets stood at $44.4 million, which was down 17.32% from $43.8 million recorded in Q2 2025.
  • In the past 5 years, Tonix Pharmaceuticals Holding's Non-Current Assets registered a high of $108.4 million during Q2 2023, and its lowest value of $43.3 million during Q1 2025.
  • Moreover, its 3-year median value for Non-Current Assets was $45.0 million (2024), whereas its average is $71.7 million.
  • Examining YoY changes over the last 5 years, Tonix Pharmaceuticals Holding's Non-Current Assets showed a top increase of 1036.37% in 2024 and a maximum decrease of 5886.36% in 2024.
  • Over the past 3 years, Tonix Pharmaceuticals Holding's Non-Current Assets (Quarter) stood at $106.7 million in 2023, then crashed by 58.86% to $43.9 million in 2024, then increased by 1.1% to $44.4 million in 2025.
  • Its Non-Current Assets stands at $44.4 million for Q3 2025, versus $43.8 million for Q2 2025 and $43.3 million for Q1 2025.